title: Effect of prior hyperglycemia on IL-6 responses to exercise in children with type 1 diabetes.
abstract: The proinflammatory cytokine interleukin-6 (IL-6) may modulate the onset and progression of complications of diabetes. As this cytokine increases after exercise, and many other exercise responses are altered by prior glycemic fluctuations, we hypothesized that prior hyperglycemia might exacerbate the IL-6 response to exercise. Twenty children with type 1 diabetes (12 boys/8 girls, age 12-15 yr) performed 29 exercise studies (30-min intermittent cycling at approximately 80% peak O2 uptake). Children were divided into four groups based on highest morning glycemic reading [blood glucose (BG) < 150, BG 151-200, BG 201-300, or BG > 300 mg/dl]. All exercise studies were performed in the late morning, after hyperglycemia had been corrected and steady-state conditions (plasma glucose < 120 mg/dl, basal insulin infusion) had been maintained for > or = 90 min. Blood samples for IL-6, growth factors, and counterregulatory hormones were drawn at pre-, end-, and 30 min postexercise time points. At all time points, circulating IL-6 was lowest in BG < 150 and progressively higher in the other three groups. The exercise-induced increment also followed a similar dose-response pattern (BG < 150, 0.6 +/- 0.2 ng/ml; BG 151-200, 1.2 +/- 0.8 ng/ml; BG 201-300, 2.1 +/- 1.1 ng/ml; BG > 300, 3.2 +/- 1.4 ng/ml). Other measured variables (growth hormone, IGF-I, glucagon, epinephrine, cortisol) were not influenced by prior hyperglycemia. Recent prior hyperglycemia markedly influenced baseline and exercise-induced levels of IL-6 in a group of peripubertal children with type 1 diabetes. While exercise is widely encouraged and indeed often considered part of diabetic management, our data underscore the necessity to completely understand all adaptive mechanisms associated with physical activity, particularly in the context of the developing diabetic child.
authors.affiliation: U.C. Irvine General Clinical Research Center, Bldg. 25, 2 Floor, 101 The City Drive, Orange, CA 92868, USA. pgalasse@uci.edu
authors.forename: P R
authors.initials: PR
authors.lastname: Galassetti
authors.forename: K
authors.initials: K
authors.lastname: Iwanaga
authors.forename: A M
authors.initials: AM
authors.lastname: Pontello
authors.forename: F P
authors.initials: FP
authors.lastname: Zaldivar
authors.forename: R L
authors.initials: RL
authors.lastname: Flores
authors.forename: J K
authors.initials: JK
authors.lastname: Larson
mesh_terms: D000293:Adolescent; D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D004837:Epinephrine / Q000097:blood; D015444:Exercise / Q000502:physiology*; D005080:Exercise Test; D005260:Female; D005934:Glucagon / Q000097:blood; D015309:Glucose Clamp Technique; D006133:Growth Substances / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D006943:Hyperglycemia / Q000097:blood / Q000503:physiopathology*; D007328:Insulin / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D010101:Oxygen Consumption / Q000502:physiology
chemical_list: D001786:Blood Glucose; D006133:Growth Substances; D007328:Insulin; D015850:Interleukin-6; D005934:Glucagon; D006854:Hydrocortisone; D004837:Epinephrine